JP6173352B2 - 筋萎縮性側索硬化症の治療方法 - Google Patents

筋萎縮性側索硬化症の治療方法 Download PDF

Info

Publication number
JP6173352B2
JP6173352B2 JP2014557799A JP2014557799A JP6173352B2 JP 6173352 B2 JP6173352 B2 JP 6173352B2 JP 2014557799 A JP2014557799 A JP 2014557799A JP 2014557799 A JP2014557799 A JP 2014557799A JP 6173352 B2 JP6173352 B2 JP 6173352B2
Authority
JP
Japan
Prior art keywords
als
compound
composition
acid
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014557799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015510517A5 (https=
JP2015510517A (ja
Inventor
ペール ギヨルストルップ，
ペール ギヨルストルップ，
Original Assignee
アニダ ファーマ インコーポレイテッド
アニダ ファーマ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アニダ ファーマ インコーポレイテッド, アニダ ファーマ インコーポレイテッド filed Critical アニダ ファーマ インコーポレイテッド
Publication of JP2015510517A publication Critical patent/JP2015510517A/ja
Publication of JP2015510517A5 publication Critical patent/JP2015510517A5/ja
Application granted granted Critical
Publication of JP6173352B2 publication Critical patent/JP6173352B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014557799A 2012-02-15 2013-02-15 筋萎縮性側索硬化症の治療方法 Expired - Fee Related JP6173352B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261599096P 2012-02-15 2012-02-15
US61/599,096 2012-02-15
PCT/US2013/026284 WO2013123290A1 (en) 2012-02-15 2013-02-15 Methods of treating amyotrophic lateral sclerosis

Publications (3)

Publication Number Publication Date
JP2015510517A JP2015510517A (ja) 2015-04-09
JP2015510517A5 JP2015510517A5 (https=) 2016-03-24
JP6173352B2 true JP6173352B2 (ja) 2017-08-02

Family

ID=48984729

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014557799A Expired - Fee Related JP6173352B2 (ja) 2012-02-15 2013-02-15 筋萎縮性側索硬化症の治療方法

Country Status (5)

Country Link
US (1) US9340483B2 (https=)
EP (1) EP2814479B1 (https=)
JP (1) JP6173352B2 (https=)
CA (1) CA2864797C (https=)
WO (1) WO2013123290A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018209681B2 (en) 2017-01-18 2023-11-16 Universitat Autonoma De Barcelona Specialized pro-resolving lipid mediators for use in the treatment of neurodegenerative diseases and/or autoimmune diseases
WO2019016580A1 (en) 2017-07-20 2019-01-24 Universitat Autonoma De Barcelona MARESINS FOR USE IN THE TREATMENT OF CNS INJURIES
US10322114B2 (en) 2017-07-31 2019-06-18 Above And Beyond Nb, Llc Formulation of a riluzole solution with beta-cyclodextrins
WO2023250031A1 (en) * 2022-06-21 2023-12-28 Anida Pharma Inc. Compositions and methods for treating hearing and ocular disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1762557B1 (en) 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
JP2005510524A (ja) 2001-11-16 2005-04-21 アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド ポリアミン経路の調節による神経変性障害の治療
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
US20040254152A1 (en) 2003-04-17 2004-12-16 Monje Michelle L. Prevention of deficits in neurogenesis with anti-inflammatory agents
US20050075398A1 (en) * 2003-08-05 2005-04-07 Bazan Nicolas G. Neuroprotectin D1 protects against cellular apoptosis, stroke damage, alzheimer's disease and retinal diseases
DK1691814T3 (da) * 2003-12-01 2012-10-29 Cambridge Entpr Ltd Antiinflammatoriske midler
WO2007041440A2 (en) 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
WO2008103753A2 (en) * 2007-02-20 2008-08-28 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
WO2009018333A2 (en) * 2007-07-30 2009-02-05 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Dha and pedf, a therapeutic composition for nerve and retinal pigment epithelial cells
GB2452696B (en) * 2007-08-02 2009-09-23 Cambridge Entpr Ltd 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
CA2699483A1 (en) 2007-09-14 2009-03-26 Resolvyx Pharmaceuticals, Inc. Compositions and methods for modulating immune function
WO2009056983A1 (en) 2007-10-31 2009-05-07 Pronova Biopharma Norge As New dha derivatives and their use as medicaments
US7782152B2 (en) 2008-08-14 2010-08-24 Broadcom Corporation Monotonic frequency tuning technique for DCXO in cellular applications
EP2393353A4 (en) 2009-02-05 2013-12-25 Resolvyx Pharmaceuticals Inc COMPOSITIONS AND METHODS OF ORGAN CONSERVATION
WO2014134184A1 (en) * 2013-02-28 2014-09-04 Anida Pharma Inc. Methods of treating ototoxicity

Also Published As

Publication number Publication date
US20150010549A1 (en) 2015-01-08
WO2013123290A9 (en) 2014-09-12
EP2814479A4 (en) 2015-07-01
CA2864797C (en) 2022-03-22
WO2013123290A1 (en) 2013-08-22
JP2015510517A (ja) 2015-04-09
CA2864797A1 (en) 2013-08-22
EP2814479A1 (en) 2014-12-24
EP2814479B1 (en) 2019-09-04
US9340483B2 (en) 2016-05-17

Similar Documents

Publication Publication Date Title
US11951109B2 (en) EZH2 inhibitors for treating lymphoma
US20240180919A1 (en) Ezh2 inhibitors for treating cancer
US11339136B2 (en) Compounds and compositions for treating conditions associated with NLRP activity
US11786533B2 (en) Use of EZH2 inhibitors for treating cancer
EP3743065A1 (en) Sulfonamide derivatives for protein degradation
AU2017253937A1 (en) Compounds and compositions for treating conditions associated with NLRP activity
JP2022513392A (ja) 活性分子送達のための胆汁酸及びそれらの誘導体の抱合体
WO2018096504A1 (en) Cbd prodrugs, compositions, and methods of administering cbd and cbd prodrugs
AU2018386223A1 (en) Small molecule degraders that recruit DCAFT15
JP2024515062A (ja) 重水素化ｄｈｏｄｈ阻害剤
JP6173352B2 (ja) 筋萎縮性側索硬化症の治療方法
CN103153975B (zh) 用于疾病治疗的新型萘醌
JP6295278B2 (ja) 聴器毒性を治療する方法
CN117586204A (zh) 异硒唑酮类化合物、其合成方法及用途
HK40122848A (zh) 双取代酰胺卟啉衍生物、其制备方法及其作为光敏剂的用途
HK40122848B (zh) 双取代酰胺卟啉衍生物、其制备方法及其作为光敏剂的用途
EP4351574A1 (en) Inhibitors of ttbk1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170515

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170608

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170704

R150 Certificate of patent or registration of utility model

Ref document number: 6173352

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees